These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

633 related articles for article (PubMed ID: 20172849)

  • 41. Low serum fetuin-A concentration predicts poor outcome only in the presence of inflammation in prevalent haemodialysis patients.
    Metry G; Stenvinkel P; Qureshi AR; Carrero JJ; Yilmaz MI; Bárány P; Snaedal S; Heimbürger O; Lindholm B; Suliman ME
    Eur J Clin Invest; 2008 Nov; 38(11):804-11. PubMed ID: 19021697
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The Phosphate Binder Ferric Citrate and Mineral Metabolism and Inflammatory Markers in Maintenance Dialysis Patients: Results From Prespecified Analyses of a Randomized Clinical Trial.
    Van Buren PN; Lewis JB; Dwyer JP; Greene T; Middleton J; Sika M; Umanath K; Abraham JD; Arfeen SS; Bowline IG; Chernin G; Fadem SZ; Goral S; Koury M; Sinsakul MV; Weiner DE;
    Am J Kidney Dis; 2015 Sep; 66(3):479-88. PubMed ID: 25958079
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Comparison of sevelamer hydrochloride and sevelamer carbonate: risk of metabolic acidosis and clinical implications.
    Pai AB; Shepler BM
    Pharmacotherapy; 2009 May; 29(5):554-61. PubMed ID: 19397463
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Phosphate binder therapy for attainment of K/DOQI bone metabolism guidelines.
    Nolan CR
    Kidney Int Suppl; 2005 Jul; (96):S7-14. PubMed ID: 15954948
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Treatment of hyperphosphatemia with sevelamer hydrochloride in CKD patients: effects on vascular calcification and mortality].
    Koizumi M; Fukagawa M
    Clin Calcium; 2010 Nov; 20(11):1700-8. PubMed ID: 21037391
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Short-term treatment with sevelamer increases serum fetuin-a concentration and improves endothelial dysfunction in chronic kidney disease stage 4 patients.
    Caglar K; Yilmaz MI; Saglam M; Cakir E; Acikel C; Eyileten T; Yenicesu M; Oguz Y; Vural A; Carrero JJ; Axelsson J; Lindholm B; Stenvinkel P
    Clin J Am Soc Nephrol; 2008 Jan; 3(1):61-8. PubMed ID: 18057307
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pleiotropic effects of sevelamer beyond phosphate binding in end-stage renal disease patients: a randomized, open-label, parallel-group study.
    Lin YF; Chien CT; Kan WC; Chen YM; Chu TS; Hung KY; Tsai TJ; Wu KD; Wu MS
    Clin Drug Investig; 2011; 31(4):257-67. PubMed ID: 21299254
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Sevelamer hydrochloride: a review of its use for hyperphosphataemia in patients with end-stage renal disease on haemodialysis.
    Goldsmith DR; Scott LJ; Cvetković RS; Plosker GL
    Drugs; 2008; 68(1):85-104. PubMed ID: 18081374
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Sevelamer carbonate lowers serum phosphorus effectively in haemodialysis patients: a randomized, double-blind, placebo-controlled, dose-titration study.
    Chen N; Wu X; Ding X; Mei C; Fu P; Jiang G; Li X; Chen J; Liu B; La Y; Hou F; Ni Z; Fu J; Xing C; Yu X; Huang C; Zuo L; Wang L; Hunter J; Dillon M; Plone M; Neylan J
    Nephrol Dial Transplant; 2014 Jan; 29(1):152-60. PubMed ID: 24151017
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A comparison of sevelamer hydrochloride with calcium acetate on biomarkers of bone turnover in hemodialysis patients.
    Liu YL; Lin HH; Yu CC; Kuo HL; Yang YF; Chou CY; Lin PW; Liu JH; Liao PY; Huang CC
    Ren Fail; 2006; 28(8):701-7. PubMed ID: 17162430
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The circulating soluble TRAIL is a negative marker for inflammation inversely associated with the mortality risk in chronic kidney disease patients.
    Liabeuf S; Barreto DV; Barreto FC; Chasseraud M; Brazier M; Choukroun G; Kamel S; Massy ZA
    Nephrol Dial Transplant; 2010 Aug; 25(8):2596-602. PubMed ID: 20190248
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effects of switching from sevelamer hydrochloride to bixalomer on laboratory parameters in hemodialysis patients.
    Furukawa K; Ikawa T; Yokoi S; Yokouchi S; Kato K; Ueno M; Takahashi J
    Ther Apher Dial; 2014 Jun; 18 Suppl 2():2-7. PubMed ID: 24975888
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Sevelamer versus calcium carbonate in incident hemodialysis patients: results of an open-label 24-month randomized clinical trial.
    Di Iorio B; Molony D; Bell C; Cucciniello E; Bellizzi V; Russo D; Bellasi A;
    Am J Kidney Dis; 2013 Oct; 62(4):771-8. PubMed ID: 23684755
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients.
    Suki WN; Zabaneh R; Cangiano JL; Reed J; Fischer D; Garrett L; Ling BN; Chasan-Taber S; Dillon MA; Blair AT; Burke SK
    Kidney Int; 2007 Nov; 72(9):1130-7. PubMed ID: 17728707
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Sevelamer hydrochloride improves hyperphosphatemia in hemodialysis patients with low bone turnover rate and low intact parathyroid hormone levels.
    Kokuho T; Toya Y; Kawaguchi Y; Tamura K; Iwatsubo K; Dobashi Y; Nakazawa A; Takeda H; Iwatsubo M; Hirawa N; Yasuda G; Ohnishi T; Umemura S
    Ther Apher Dial; 2007 Dec; 11(6):442-8. PubMed ID: 18028171
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effect of gastric acid suppression with pantoprazole on the efficacy of sevelamer hydrochloride as a phosphate binder in haemodialysis patients: a pilot study.
    Lai B; Cervelli MJ
    Nephrology (Carlton); 2012 May; 17(4):402-6. PubMed ID: 22329674
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Reduction of hyperphosphatemia is related with the reduction of C-reactive protein in dialysis patients. Study in sevelamer-resistant dialysis patients treated with chitosan chewing gum as salivary phosphate binder.
    Calò LA; Savica V; Piccoli A; Fusaro M; D'Angelo A; Davis PA
    Ren Fail; 2011; 33(1):11-4. PubMed ID: 21219199
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Comparison of calcium acetate and sevelamer on vascular function and fibroblast growth factor 23 in CKD patients: a randomized clinical trial.
    Yilmaz MI; Sonmez A; Saglam M; Yaman H; Kilic S; Eyileten T; Caglar K; Oguz Y; Vural A; Yenicesu M; Mallamaci F; Zoccali C
    Am J Kidney Dis; 2012 Feb; 59(2):177-85. PubMed ID: 22137672
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The pathophysiology of early-stage chronic kidney disease-mineral bone disorder (CKD-MBD) and response to phosphate binders in the rat.
    Moe SM; Radcliffe JS; White KE; Gattone VH; Seifert MF; Chen X; Aldridge B; Chen NX
    J Bone Miner Res; 2011 Nov; 26(11):2672-81. PubMed ID: 21826734
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Peripheral vascular calcification in long-haemodialysis patients: associated factors and survival consequences.
    Jean G; Bresson E; Terrat JC; Vanel T; Hurot JM; Lorriaux C; Mayor B; Chazot C
    Nephrol Dial Transplant; 2009 Mar; 24(3):948-55. PubMed ID: 18852190
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 32.